Therapeutic Responses of Plasmodium vivax Malaria to Chloroquine and Primaquine Treatment in Northeastern Myanmar
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Chloroquine-primaquine (CQ-PQ) continues to be the frontline therapy for radical cure of Plasmodium vivax malaria. Emergence of CQ-resistant (CQR) P. vivax parasites requires a shift to artemisinin combination therapies (ACTs), which imposes a significant financial, logistical, and safety burden. Monitoring the therapeutic efficacy of CQ is thus important. Here, we evaluated the therapeutic efficacy of CQ-PQ for P. vivax malaria in northeast Myanmar. We recruited 587 patients with P. vivax monoinfection attending local malaria clinics during 2012 to 2013. These patients received three daily doses of CQ at a total dose of 24 mg of base/kg of body weight and an 8-day PQ treatment (0.375 mg/kg/day) commencing at the same time as the first CQ dose. Of the 401 patients who finished the 28-day follow-up, the cumulative incidence of recurrent parasitemia was 5.20% (95% confidence interval [CI], 3.04% to 7.36%). Among 361 (61%) patients finishing a 42-day follow-up, the cumulative incidence of recurrent blood-stage infection reached 7.98% (95% CI, 5.20% to 10.76%). The cumulative risk of gametocyte carriage at days 28 and 42 was 2.21% (95% CI, 0.78% to 3.64%) and 3.93% (95% CI, 1.94% to 5.92%), respectively. Interestingly, for all 15 patients with recurrent gametocytemia, this was associated with concurrent asexual stages. Genotyping of recurrent parasites at the merozoite surface protein 3α gene locus from 12 patients with recurrent parasitemia within 28 days revealed that 10 of these were the same genotype as at day 0, suggesting recrudescence or relapse. Similar studies in 70 patients in the same area in 2007 showed no recurrent parasitemias within 28 days. The sensitivity to chloroquine of P. vivax in northeastern Myanmar may be deteriorating.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These rates are consistent with studies from Northeastern Myanmar (94.8%) [24] and Northwestern Ethiopia (92.6%) [25].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The changing epidemiology of malaria elimination: New strategies for new challenges
Cotter, C., Sturrock, H. J., Hsiang, M. S., Liu, J., Phillips, A. A., Hwang, J., Gueye, C. S., Fullman, N., Gosling, R. D., & Feachem, R. G. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60310-4 · Cited by 671 · cited 1×
“falciparum are coendemic, intensified control efforts have led to major changes in malaria epidemiology, and the problem of vivax malaria has become more prominent (4).”
BackgroundShrinking the malaria map: progress and prospects
Feachem, R. G., Phillips, A. A., Hwang, J., Cotter, C., Wielgosz, B., Greenwood, B. M., Sabot, O., Rodriguez, M. H., Abeyasinghe, R. R., Ghebreyesus, T. A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61270-6 · Cited by 429 · cited 1×
“With emerging global interests in malaria elimination (5), many nations in which vivax malaria is endemic will inevitably face greater challenges for the control and elimination of this parasite.”
Malaria in the Greater Mekong Subregion: heterogeneity and complexity.
Cui, L., Yan, G., Sattabongkot, J., Cao, Y., Chen, B., Chen, X., Fan, Q., Fang, Q., Jongwutiwes, S., Parker, D., et al. (2012) · Acta Tropica · doi:10.1016/j.actatropica.2011.02.016 · Cited by 277 · cited 6×
“Within Myanmar, malaria is distributed unevenly, and the regions with the highest malaria burdens border China, Thailand, and India and represent pools of infection which could frustrate efforts of neighboring countries in their progress toward malaria elimination (15, 16).”
BackgroundInfluentialSelf-citationChloroquine resistant vivax malaria in a pregnant woman on the western border of Thailand
Rijken, M. J., Boel, M. E., Russell, B., Imwong, M., Leimanis, M. L., Phyo, A. P., Muehlenbachs, A., Lindegardh, N., McGready, R., Rénia, L., et al. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-113 · Cited by 62
Research works printed but not linked: 41
- 10.1371/journal.pntd.0001814 · DOI · Paper page
- 10.1016/S1473-3099(04)01043-6 · DOI · Paper page
- 10.4269/ajtmh.2007.77.79 · DOI · Paper page
- 10.1128/CMR.00008-09 · DOI · Paper page
- 10.1128/AAC.01296-10 · DOI
- 10.1016/S0140-6736(89)91792-3 · DOI · Paper page
- 10.1016/0035-9203(92)90531-G · DOI · Paper page
- 10.4269/ajtmh.1991.44.547 · DOI · Paper page
- 10.1093/infdis/164.1.222 · DOI
- 10.1056/NEJM199103283241317 · DOI
- 10.1016/S1473-3099(14)70855-2 · DOI · Paper page
- 10.1016/j.pt.2012.08.005 · DOI
- Delacollette C, D'Souza C, Christophel E, Thimasarn K, Abdur R, Bell D, Dai TC, Gopinath D, Lu S, Mendoza R, Ortega L, Rastogi R, Tantinimitkul C, Ehrenberg J. 2009. Malaria trends and challenges in the Greater Mekong Subregion. Southeast Asian J Trop Med Public Health 40:674–691.
- 10.1016/0035-9203(93)90294-Z · DOI
- 10.1016/0035-9203(95)90556-1 · DOI
- 10.1111/j.1365-3156.2007.01978.x · DOI
- 10.1186/1475-2875-12-361 · DOI
- 10.4269/ajtmh.1999.61.518 · DOI
- 10.4269/ajtmh.2003.68.613 · DOI
- 10.4269/ajtmh.1997.56.627 · doi:10.4269/ajtmh.1997.56.627
- 10.4269/ajtmh.2010.09-0428 · doi:10.4269/ajtmh.2010.09-0428
- 10.1093/infdis/169.4.932 · DOI
- 10.1016/j.bcp.2005.07.021 · doi:10.1016/j.bcp.2005.07.021
- Baird JK, Wiady I, Sutanihardja A, Suradi Purnomo Basri H, Sekartuti Ayomi E, Fryauff DJ, Hoffman SL. 2002. Short report: therapeutic efficacy of chloroquine combined with primaquine against Plasmodium falciparum in northeastern Papua, Indonesia. Am J Trop Med Hyg 66:659–660. · DOI
- 10.1093/infdis/171.6.1678 · DOI
- 10.1016/S0035-9203(99)90149-9 · DOI
- 10.1128/AAC.44.6.1680-1685.2000 · DOI · Paper page
- 10.1016/j.trstmh.2005.04.024 · DOI
- 10.1186/1475-2875-10-44 · DOI
- Vijaykadga S, Rojanawatsirivej C, Congpoung K, Wilairatana P, Satimai W, Uaekowitchai C, Pumborplub B, Sittimongkol S, Pinyorattanachote A, Prigchoo P. 2004. Assessment of therapeutic efficacy of chloroquine for vivax malaria in Thailand. Southeast Asian J Trop Med Public Health 35:566–569.
- Congpoung K, Satimai W, Sujariyakul A, Intanakom S, Harnpitakpong W, Pranuth Y, Cholpol S, Bualombai P. 2011. In vivo sensitivity monitoring of chloroquine for the treatment of uncomplicated vivax malaria in four bordered provinces of Thailand during 2009-2010. J Vector Borne Dis 48:190–196.
- 10.1186/1475-2875-13-364 · DOI
- 10.1093/cid/cir631 · DOI · Paper page
- Liang GL, Sun XD, Wang J, Zhang ZX. 2009. Sensitivity of Plasmodium vivax to chloroquine in Laza City, Myanmar. Chin J Parasitol Parasitic Dis 27:175–176. (In Chinese.)
- 10.1016/0140-6736(93)92568-E · DOI · Paper page
- 10.4269/ajtmh.2003.69.548 · doi:10.4269/ajtmh.2003.69.548
- 10.1155/2012/936067 · doi:10.1155/2012/936067
- 10.4269/ajtmh.2008.79.378 · DOI
- 10.1093/infdis/jit261 · DOI
- 10.1086/512241 · DOI · Paper page
- 10.1016/S1473-3099(10)70079-7 · DOI · Paper page
Cited by
Antimalarial Drug Resistance: Literature Review and Activities and Findings of the ICEMR Network
Cui, L., Mharakurwa, S., Ndiaye, D., Rathod, P. K., & Rosenthal, P. J. (2015) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.15-0007 · Cited by 305
Self-citationGetu, E., Biruksew, A., Eshetu, T., Abamecha, A., Assefa, D. G., Mohammed, H., Wuletaw, Y., Tasew, G., Tollera, G., Hailu, M., et al. (2025) · Malaria Journal · doi:10.1186/s12936-025-05446-y · Cited by 4
Metadata
- Authors
- Yuan, L., Wang, Y., Parker, D. M., Gupta, B., Yang, Z., Liu, H., Fan, Q., Cao, Y., Xiao, Y., Lee, M.-C., Zhou, G., Yan, G., Baird, J. K., & Cui, L.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2015-02
- Volume
- 59
- Issue
- 2
- Pages
- 1230-1235
- ISSN
- 0066-4804
- 1098-6596
- Cited by
- 50
- References
- 4
- Language
- en
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.